Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors.
LADC
lung adenocarcinoma
obstruction
smoking
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
30
11
2018
revised:
24
01
2019
accepted:
27
01
2019
pubmed:
26
2
2019
medline:
8
5
2020
entrez:
27
2
2019
Statut:
ppublish
Résumé
A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early-stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never-smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians (P < 0.0001). Ever-smoker tumors were preferentially localized to the upper lobes. We observed 120 relapses and 74 deaths over 704 cumulative follow-up years. Median overall and disease-free survival were >7.5 and 3.6 years, respectively. Patients aged <45 or >65 years, resected >60 days postdiagnosis, with abnormal FVC/DL
Identifiants
pubmed: 30806043
doi: 10.1002/cam4.2031
pmc: PMC6488114
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1486-1499Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Lung Cancer. 2014 May;84(2):145-50
pubmed: 24598367
Respir Med. 2015 Dec;109(12):1553-61
pubmed: 26564001
Tumour Biol. 2015 Jul;36(7):4979-86
pubmed: 25677900
BMC Cancer. 2012 Jun 18;12:250
pubmed: 22708674
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
ERJ Open Res. 2017 Jul 12;3(3):
pubmed: 28717642
PLoS One. 2015 Feb 23;10(2):e0117628
pubmed: 25706152
Nat Rev Cancer. 2013 Apr;13(4):233-45
pubmed: 23467302
J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
pubmed: 10413421
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Chest. 1981 Dec;80(6 Suppl):898-901
pubmed: 7307633
Cancer Cell. 2013 Oct 14;24(4):410-21
pubmed: 24135279
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
Acta Oncol. 2017 Mar;56(3):448-454
pubmed: 27846762
Chest. 2013 May;143(5 Suppl):e369S-e399S
pubmed: 23649447
Chest. 2013 May;143(5 Suppl):e1S-e29S
pubmed: 23649439
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Am J Respir Crit Care Med. 2013 Oct 15;188(8):907-12
pubmed: 23721055
Ann Intern Med. 1975 Jun;82(6):739-45
pubmed: 1094879
J Clin Oncol. 2012 May 1;30(13):1438-46
pubmed: 22393100
Nat Med. 2001 Jul;7(7):833-9
pubmed: 11433349
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Feb;53(2):152-8
pubmed: 20127297
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2345-52
pubmed: 24882061
Am J Respir Crit Care Med. 2015 Jan 1;191(1):19-33
pubmed: 25369325
OMICS. 2010 Feb;14(1):109-13
pubmed: 20141333
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278
Cancer Med. 2019 Apr;8(4):1486-1499
pubmed: 30806043